3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
27
Lymphoid
8
Thoracic
2
Sarcoma
2
Other hematologic neoplasm
2
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Solid Tumor
1
Interventions
Cisplatin
42
Pemetrexed
31
Carboplatin
28
Nivolumab
21
pembrolizumab
19
Gemcitabine
19
atezolizumab
13
Etoposide
13
Injections
12
Ipilimumab
11
Cyclophosphamide
11
Radiotherapy
10
Oxaliplatin
10
Filgrastim
10
Docetaxel
10
Bevacizumab
10
tislelizumab
9
Vincristine
9
Specimen Handling
9
durvalumab
8
Paclitaxel
8
Capecitabine
8
tremelimumab
7
toripalimab
7
lenvatinib
7
Everolimus
7
spartalizumab
6
olaparib
6
niraparib
6
Vinorelbine
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lomustine
×
Other solid neoplasm
×
Clear all
NCT05898451
2023-06-12
R-2
Refnot-Pharm Ltd
Phase 2
Completed
55 enrolled